Press release from PR Newswire
Medivation Announces Participation in 13th Annual BIO CEO & Investor Conference
Monday, February 07, 2011
SAN FRANCISCO, Feb. 7, 2011 /PRNewswire/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that David Hung, M.D., president and chief executive officer, will present at the 13th Annual BIO CEO & Investor Conference on Monday, February 14, at 10:30 a.m. Eastern Time at the Waldorf-Astoria in New York.
Dr. Hung will provide an overview of Medivation and its clinical development programs for MDV3100 for prostate cancer and dimebon (latrepirdine) for Alzheimer's and Huntington diseases.
Live audio webcasts of the presentation will be available on the "Events and Presentations" page of the "Investor Relations" section of the Company's website at www.medivation.com. A replay also will be available for 30 days following the live presentation.
Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. Together with its corporate partners Pfizer and Astellas, Medivation currently has investigational drugs in Phase 3 development to treat advanced prostate cancer, mild-to-moderate Alzheimer's disease and Huntington disease. For more information, please visit us at www.medivation.com.
SOURCE Medivation, Inc.
For further information: Patrick Machado, Chief Financial Officer of Medivation, Inc., +1-415-829-4101; or Nicole Foderaro of WCG, +1-415-946-1058, for Medivation, Inc.